Compare PSTV & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTV | UPXI |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 151.0M |
| IPO Year | N/A | 2021 |
| Metric | PSTV | UPXI |
|---|---|---|
| Price | $0.55 | $1.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.25 | $6.00 |
| AVG Volume (30 Days) | ★ 5.3M | 4.2M |
| Earning Date | 10-30-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.85 |
| Revenue | $5,258,000.00 | ★ $20,694,575.00 |
| Revenue This Year | $28.21 | $145.75 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | ★ N/A | $1.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.86 |
| 52 Week High | $2.31 | $22.57 |
| Indicator | PSTV | UPXI |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 29.11 |
| Support Level | $0.53 | $1.86 |
| Resistance Level | $0.60 | $2.12 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.05 | 3.88 |
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.